Happy Holidays
Thank you for a productive and inspiring year 2025. As 2025 comes to a close, we take a moment to reflect and to look forward.
Main achievements of 2025 include:
Recruitment completed
End of April 2025 the last patient was included in the prospective study. While follow-up will run until April 2026, this is a huge milestone, and we thank all sites for their efforts. Data upload is almost complete.Recruitment started
The first clinical study using LIPUS in UC patients was approved by the Ethical Committee and the Italian Ministry of Health and officially launched in March 2025.Advances toward integration
During the 2025 Progress Meetings partners reported major milestones in multi-omics analyses (DPP) and data harmonization. The meeting also showcased first results from comparative studies across atopic dermatitis and ulcerative colitis, strengthening the consortium’s direction toward identifying shared mechanisms and clinically relevant biomarkers.Strong scientific visibility at major conferences
ImmUniverse partners actively contributed to DDW, UEG Week and ECCO, but also presented related results at various other opportunities.Enhanced outreach and dissemination efforts
Throughout the year, the consortium published new articles, interviews, and lay summaries, including contributions to the ECCO news and IFCCA Project Digests. HUNIMED produced a videoclip on LIPUS and we started awareness campaign for the World IBD Day and World Atopic Eczema Day. These efforts continue to increase the visibility of the project, foster dialogue with the broader scientific community, and make our research more accessible to patients and the public.
As we look ahead to 2026, our resolve to reach the next milestones and pioneer a future with improved diagnostic and therapeutic options for people living with ulcerative colitis and atopic dermatitis is stronger than ever.
From all of us at ImmUniverse, we wish you a joyful holiday season and a healthy, successful, and fulfilling start to the new year.
